Previous Article | Next Article 
Infect Immun, May 1998, p. 2018-2025, Vol. 66, No. 5
0019-9567/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Antibodies to Recombinant Clostridium
difficile Toxins A and B Are an Effective Treatment and Prevent
Relapse of C. difficile-Associated Disease in a
Hamster Model of Infection
John A.
Kink* and
Jim A.
Williams
Ophidian Pharmaceuticals, Inc., Madison,
Wisconsin
Received 12 December 1997/Returned for modification 13 February
1998/Accepted 25 February 1998
Clostridium difficile causes antibiotic-associated
diarrhea and colitis in humans through the actions of toxin A and toxin B on the colonic mucosa. At present, broad-spectrum antibiotic drugs
are used to treat this disease, and patients suffer from high relapse
rates after termination of treatment. This study examined the role of
both toxins in pathogenesis and the ability of orally administered
avian antibodies against recombinant epitopes of toxin A and toxin B to
treat C. difficile-associated disease (CDAD). DNA fragments
representing the entire gene of each toxin were cloned, expressed, and
affinity purified. Hens were immunized with these purified
recombinant-protein fragments of toxin A and toxin B. Toxin-neutralizing antibodies fractionated from egg yolks were
evaluated by a toxin neutralization assay in Syrian hamsters. The
carboxy-terminal region of each toxin was most effective in generating
toxin-neutralizing antibodies. With a hamster infection model,
antibodies to both toxins A and B (CDAD antitoxin) were required to
prevent morbidity and mortality from infection. In contrast to
vancomycin, CDAD antitoxin prevented relapse and subsequent C. difficile reinfection in the hamsters. These results indicate that CDAD antitoxin may be effective in the treatment and management of
CDAD in humans.
*
Corresponding author. Mailing address: Ophidian
Pharmaceuticals, Inc., 5445 East Cheryl Pkwy., Madison, WI 53711. Phone: (608) 271-0878. Fax: (608) 277-2395. E-mail: ophidian{at}ophd.com.

Present address: BioNebraska, Lincoln, NE 68524.
Infect Immun, May 1998, p. 2018-2025, Vol. 66, No. 5
0019-9567/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Goulding, D., Thompson, H., Emerson, J., Fairweather, N. F., Dougan, G., Douce, G. R.
(2009). Distinctive Profiles of Infection and Pathology in Hamsters Infected with Clostridium difficile Strains 630 and B1. Infect. Immun.
77: 5478-5485
[Abstract]
[Full Text]
-
Monaghan, T, Boswell, T, Mahida, Y R
(2009). Recent advances in Clostridium difficile-associated disease. Postgrad. Med. J.
85: 152-162
[Abstract]
[Full Text]
-
Pauly, D., Dorner, M., Zhang, X., Hlinak, A., Dorner, B., Schade, R.
(2009). Monitoring of laying capacity, immunoglobulin Y concentration, and antibody titer development in chickens immunized with ricin and botulinum toxins over a two-year period. Poult. Sci.
88: 281-290
[Abstract]
[Full Text]
-
Monaghan, T, Boswell, T, Mahida, Y R
(2008). Recent advances in Clostridium difficile-associated disease. Gut
57: 850-860
[Abstract]
[Full Text]
-
Babcock, G. J., Broering, T. J., Hernandez, H. J., Mandell, R. B., Donahue, K., Boatright, N., Stack, A. M., Lowy, I., Graziano, R., Molrine, D., Ambrosino, D. M., Thomas, W. D. Jr.
(2006). Human Monoclonal Antibodies Directed against Toxins A and B Prevent Clostridium difficile-Induced Mortality in Hamsters. Infect. Immun.
74: 6339-6347
[Abstract]
[Full Text]
-
Aboudola, S., Kotloff, K. L., Kyne, L., Warny, M., Kelly, E. C., Sougioultzis, S., Giannasca, P. J., Monath, T. P., Kelly, C. P.
(2003). Clostridium difficile Vaccine and Serum Immunoglobulin G Antibody Response to Toxin A. Infect. Immun.
71: 1608-1610
[Abstract]
[Full Text]
-
Kurtz, C. B., Cannon, E. P., Brezzani, A., Pitruzzello, M., Dinardo, C., Rinard, E., Acheson, D. W. K., Fitzpatrick, R., Kelly, P., Shackett, K., Papoulis, A. T., Goddard, P. J., Barker, R. H. Jr., Palace, G. P., Klinger, J. D.
(2001). GT160-246, a Toxin Binding Polymer for Treatment of Clostridium difficile Colitis. Antimicrob. Agents Chemother.
45: 2340-2347
[Abstract]
[Full Text]
-
Mylonakis, E., Ryan, E. T., Calderwood, S. B.
(2001). Clostridium difficile-Associated Diarrhea: A Review. Arch Intern Med
161: 525-533
[Abstract]
[Full Text]
-
Kotloff, K. L., Wasserman, S. S., Losonsky, G. A., Thomas, W. Jr., Nichols, R., Edelman, R., Bridwell, M., Monath, T. P.
(2001). Safety and Immunogenicity of Increasing Doses of a Clostridium difficile Toxoid Vaccine Administered to Healthy Adults. Infect. Immun.
69: 988-995
[Abstract]
[Full Text]
-
Alfa, M. J., Kabani, A., Lyerly, D., Moncrief, S., Neville, L. M., Al-Barrak, A., Harding, G. K. H., Dyck, B., Olekson, K., Embil, J. M.
(2000). Characterization of a Toxin A-Negative, Toxin B-Positive Strain of Clostridium difficile Responsible for a Nosocomial Outbreak of Clostridium difficile-Associated Diarrhea. J. Clin. Microbiol.
38: 2706-2714
[Abstract]
[Full Text]
-
Genth, H., Selzer, J., Busch, C., Dumbach, J., Hofmann, F., Aktories, K., Just, I.
(2000). New Method To Generate Enzymatically Deficient Clostridium difficile Toxin B as an Antigen for Immunization. Infect. Immun.
68: 1094-1101
[Abstract]
[Full Text]
-
Stubbe, H., Berdoz, J., Kraehenbuhl, J.-P., Corthesy, B.
(2000). Polymeric IgA Is Superior to Monomeric IgA and IgG Carrying the Same Variable Domain in Preventing Clostridium difficile Toxin A Damaging of T84 Monolayers. J. Immunol.
164: 1952-1960
[Abstract]
[Full Text]
-
Giannasca, P. J., Zhang, Z.-x., Lei, W.-d., Boden, J. A., Giel, M. A., Monath, T. P., Thomas, W. D. Jr.
(1999). Serum Antitoxin Antibodies Mediate Systemic and Mucosal Protection from Clostridium difficile Disease in Hamsters. Infect. Immun.
67: 527-538
[Abstract]
[Full Text]